Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions and methods for treating multiple sclerosis

An inflammatory, water-based fluid technology for drug combination, drug delivery, pharmaceutical formulation, etc.

Active Publication Date: 2011-05-25
REVALESIO CORP
View PDF14 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Conversely, however, mice lacking TSLPR failed to develop asthma in response to inhaled antigens (Zhou et al., supra, and Al-Shami et al., J. Exp. Med., 202:829-839, 2005)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for treating multiple sclerosis
  • Compositions and methods for treating multiple sclerosis
  • Compositions and methods for treating multiple sclerosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0349] refer to Figure 12 , depicts mixing device 5000. Mixing device 5000 is an alternative embodiment of mixing device 100 . Components of the mixing device 5000 that correspond substantially similarly to components of the mixing device 100 are designated herein using the same reference numerals. Only components of the mixing device 5000 that are different from those of the mixing device 100 will be described.

[0350] The mixing device 5000 includes a housing 5500 for accommodating a rotor 600 and a stator 5700 . The stator 5700 may be non-rotatably connected to the housing 5500 by its first end portion 5712 and its second end portion 5714 . A chamber 5800 is defined between the housing 5500 and a portion 5820 of the stator 5700 flanked by a first end portion 5712 and a second end portion 5714 . Housing 5500 includes an inlet 5830 that provides access to chamber 5800 . The inlet 5830 may be oriented substantially perpendicular to the axis of rotation "α". However, th...

Embodiment 1

[0495] Dissolved Oxygen Stability

[0496] Such as Figure 30 Shown in , graphically illustrates dissolved oxygen levels in 500ml thin-walled plastic bottles and 1000ml glass bottles, each capped and stored at 65 degrees Fahrenheit.

[0497] As can be seen, when the plastic bottle was opened about 65 days after bottling, the dissolved oxygen level in the water was about 27.5 ppm. When the second bottle was opened about 95 days after bottling, the dissolved oxygen level was about 25 ppm. Likewise, for the glass bottles, the dissolved oxygen level was about 40 ppm on day 65 and about 41 ppm on day 95. Thus, the graph shows that when oxygen is diffused into the fluid using the described systems and methods, the dissolved oxygen levels in both plastic and glass bottles remain at relatively high rates at 65° Fahrenheit.

Embodiment 2

[0499] Declining Oxygen Content in Balanced Salt Solution

[0500] Figure 33 The dissolved oxygen retention of 500 ml of balanced salt solution initially having a dissolved oxygen level of 5 ppm is illustrated. After enriching the solution with the diffuser of the present invention, the dissolved oxygen level was about 41 ppm at standard temperature and pressure. Keep the solution in an amber glass bottle. After 1 hour, the dissolved oxygen level was 40 ppm; after 2 hours it was 36 ppm; after 3 hours it was 34 ppm; after about 4.5 hours it was just over 30 ppm. The final measurement was taken just before 6 hours when the dissolved oxygen level was about 28 ppm.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating inflammatory neurodegenerative condition or disease or at least one symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions.

Description

technical field [0001] Particular aspects relate generally to inflammatory neurodegenerative diseases including, but not limited to, multiple sclerosis (e.g., multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, stroke / cerebral ischemia, head trauma, spinal cord injury, Huntington's disease, migraine, cerebral amyloid angiopathy, AIDS-related inflammatory neurodegenerative disorders, age-related cognitive decline; mild cognitive impairment and mammalian prion diseases) and those involved in modulating or modulating neuroinflammation , and more particularly to methods for treating or preventing multiple sclerosis or inflammatory neurodegenerative diseases in a subject by administering a therapeutic composition comprising at least one electrokinetically generated fluid (e.g., an electrokinetically generated oxygen-enriched fluid) of the present invention Compositions and methods for at least one symptom of . Treatment of certain aspects i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/00
CPCA61K33/00A61K31/573A61P17/02A61P21/02A61P25/00A61P25/06A61P25/14A61P25/16A61P25/28A61P31/18A61P43/00A61P9/00A61P9/10A61K2300/00
Inventor 理查德·L·华森安东尼·B·伍德格雷戈里·J·阿咸宾
Owner REVALESIO CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com